Patents Assigned to THERAPEUTICS, INC.
  • LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES
    Publication number: 20240158336
    Abstract: Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.
    Type: Application
    Filed: November 3, 2023
    Publication date: May 16, 2024
    Applicant: Orna Therapeutics, Inc.
    Inventors: Allen T. HORHOTA, Junghoon YANG, Kevin J. KAUFFMAN, Thomas BARNES, Robert Alexander WESSELHOEFT, Amy M. BECKER, Gregory MOTZ
  • EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
    Publication number: 20240158418
    Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 16, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO
    Publication number: 20240156827
    Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.
    Type: Application
    Filed: January 22, 2024
    Publication date: May 16, 2024
    Applicant: Respira Therapeutics, Inc.
    Inventors: Zhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan
  • Transdural electrode device for stimulation of the spinal cord
    Patent number: 11980757
    Abstract: The spinal cord stimulation device of this invention is configured for implantation into a patient so as to traverse the dura mater that surrounds the spinal cord. Placing the device in this location provides direct contact between the electrode and the cerebrospinal fluid (CSF), in close proximity to the spinal cord. The device has an intradural portion and an extradural portion that compresses and seals the dural membrane between them, securing the device in position and preventing leakage of CSF. The position of the device may be stabilized in relation to the spinal cord by way of a laminoplasty plate, bridging between the device and a vertebra. The device is electronically powered by an implanted pulse generator that produces a spectrum of signals to interrupt or otherwise attenuate transmission of pain mediating neural signals through the spinal cord.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 14, 2024
    Assignees: University of Iowa Research Foundation, University Of Virginia Patent Foundation, Direct Spinal Therapeutics Inc.
    Inventors: Matthew A. Howard, George T. Gillies, Logan Helland, Royce Woodroffe, Charles Romans, Saul Wilson, Daryl R. Kipke, David J. Anderson, Daniel J. O'Connell
  • RNA-guided nucleases and active fragments and variants thereof and methods of use
    Patent number: 11981916
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 14, 2024
    Assignee: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
  • Compositions for treating neurodegenerative diseases
    Patent number: 11981636
    Abstract: The present disclosure relates to novel compounds of Formula I wherein each of Ra, Rb, Rd and Re is independently H; Rc is selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF3, SO2CH3, and morpholino, R1 is selected from the group consisting of hydrogen, alkyl, phenyl, or —CH?C(CH3)2; and R2 is specific substituted cyclic amino groups. The invention also discloses pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurogenerative diseases, including Alzheimer's disease and cognitive decline.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: May 14, 2024
    Assignee: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. Rishton, Gary C. Look, Susan M. Catalano
  • Methods of treating malignant lymphoproliferative disorders
    Patent number: 11980607
    Abstract: Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3? inhibitor, for example 9-ING-41, are provided. Also provided are methods for treating malignant lymphoproliferative disorders comprising administering a GSK-3? inhibitor, for example 9-ING-41, in combination with a second or multiple therapeutic agents.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: May 14, 2024
    Assignee: ACTUATE THERAPEUTICS INC.
    Inventors: Francis Giles, Andrew Mazar
  • Polynucleotide constructs
    Patent number: 11981703
    Abstract: Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical{circumflex over (?)} enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: May 14, 2024
    Assignee: SIRIUS THERAPEUTICS, INC.
    Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Laxman Eltepu, Bryan R. Meade, Son Lam
  • Acyclic thiol prodrugs
    Patent number: 11981694
    Abstract: Disclosed herein are acyclic thiol prodrugs, and pharmaceutical compositions thereof. The prodrugs and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example cystinosis, cystinuria, cancer neurodegenerative disease, Parkinson's disease, Huntington's disease, malaria, nonalcoholic fatty liver disease, radiation poisoning, arsenic poisoning, radioprotection, Wilson's disease or rheumatoid arthritis.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: May 14, 2024
    Assignee: Lilac Therapeutics, Inc.
    Inventors: Manoj Chandrasinhji Desai, Siva R. Kamma
  • Monospecific and bispecific antibodies and antigen binding fragments thereof
    Patent number: 11981727
    Abstract: Isolated monospecific and bispecific anti-properdin antibodies or antigen binding fragments thereof for use in treating complement mediated disorders.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: May 14, 2024
    Assignee: NOVELMED THERAPEUTICS, INC
    Inventor: Rekha Bansal
  • Activatable interleukin-2 polypeptides and methods of use thereof
    Patent number: 11981716
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: May 14, 2024
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Antibody agents specific for human CD19 and uses thereof
    Patent number: 11981742
    Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 14, 2024
    Assignee: Eureka Therapeutics, Inc.
    Inventors: Hong Liu, Jingwei Lu, Zhiyuan Yang, Li Long, Neal Cheng
  • DNA modifying enzymes and active fragments and variants thereof and methods of use
    Patent number: 11981940
    Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 14, 2024
    Assignee: LifeEDIT Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
  • Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
    Patent number: 11981672
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: May 14, 2024
    Assignee: Montelino Therapeutics Inc.
    Inventors: Jenny Desantis, Roy Joseph Vaz, Michela Eleuteri
  • Macrocyclic compounds and uses thereof
    Patent number: 11981684
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: May 14, 2024
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Methods and compositions for treating cancer
    Patent number: 11980615
    Abstract: This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: May 14, 2024
    Assignee: Zetagen Therapeutics, Inc.
    Inventors: Bryan S. Margulies, Nikhil A. Thakur
  • Engineering AAV
    Patent number: 11981967
    Abstract: The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: May 14, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Kyle McGovern, David S. Ojala
  • TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20240148675
    Abstract: The present disclosure provides novel topical compositions comprising endoxifen and salts and solvates thereof and methods for making the compositions. Certain compounds have been combined to make a stable topical compositions comprising endoxifen. The present disclosure also provides methods for treatment of hormone-dependent breast and hormone-dependent reproductive tract disorders.
    Type: Application
    Filed: June 20, 2023
    Publication date: May 9, 2024
    Applicant: Atossa Therapeutics, Inc.
    Inventors: Steven C. Quay, Avadhesh S. Kushwaha, Edward T. Kisak, John M. Newsam
  • TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS
    Publication number: 20240150349
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Application
    Filed: September 8, 2023
    Publication date: May 9, 2024
    Applicant: FORMA Therapeutics, Inc.
    Inventors: Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
    Publication number: 20240150369
    Abstract: This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.
    Type: Application
    Filed: April 20, 2023
    Publication date: May 9, 2024
    Applicant: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum